This finding could have significant treatment potential for the reduction of FFM loss under hypoxic conditions, which might be achieved with the help of dipeptidyl peptidase-IV (DPP-IV) inhibitors or GLP-1 analogues such as exendin-4, a pharmacological approach now commonly used for diabetes treatment. The gene discussed is GCG; the disease is diabetes mellitus.